

FLORIDA MEDICAID

Prior Authorization

Growth Hormone for HIV Wasting in Adults



Serostim®

	nt's Medic	aid ID#						Da	te of	Birth	ו (MM	/DD/	YYY	Y)										
										1			1]						
										'			'											
cipie	nt's Full N	ame								1		<u> </u>	<u> </u>	<u> </u>									<u> </u>	1
escril	per's Full	Name							-															
escril	ber's NPI			<u>г г</u>	<u> </u>																			
escril	ber Phone	Numbe												Pres	scrib	or Fa	ix Ni	ımbe	r					
			<u> </u>	ΙΓ																				
																					-			
1. 2.	Diagnosis Is recipier 1)	nt curren	tly on I	HAAR 2) _	RT Re	egime	n (if s): 3)						4)								1	
3.	Weight 6	months	prior/da	ate:			lb(s)/		;	We	ight 3	3 mo	nths	prior/	date			lt	o(s)/da	ate			
4.	Current B	MI/date:		_/				Curre	nt we	ight/o	date:			lb(s)	/			ł	neight	:		_(ft a	nd ir	I)
5.	Has the re psychoso												calo	ric int	ake (anor	exia)	, to r	ule o	ut mal	labs	orpti	on, a	Ind
6.	If the reci	pient has	inade	quate	; calo	oric int	take a	and ar	norexi	a ha	s ther	e bee	en a	trial c	of an a	appe	tite s	timu	lant?		Ye	s [] No	
	If yes, ind		-																					
	Drug/dire															to)							
7.	Has it bee						active	e neop	olasia	?		Yes		No										
8.	Is the rec							🗌 No					_											
	If yes, is o								•									-		_				
9.	Has the re	•											•	•			,							
	Documen								e: Dr	ug/d	irectio	ns _											;	
	Dates:																							
10	If no trial Is the Ser				•				idalia	no fo		h+2												-
	Previous		•					•			r weig	jiit?		res		0								
11.	Start date							ight:				lb(c)												
		·						ight: _							BMI:									
	End data:						~ ~ ~ ~ -	NULL.																

Phone number for non-specialty Prior Authorization: 877-433-7643 Phone number for specialty Prior Authorization: 866-814-5506 Fax number for non-specialty Prior Authorization: 866-255-7569 Fax number for non-specialty Prior Authorization: 866-249-6155 **Confidentiality Notice:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender (via return fax) immediately and arrange for the return or destruction of these documents. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient is strictly prohibited.



FLORIDA MEDICAID

PROTOCOL



Serostim[®]

Initial approval period is for a total of ninety (90) days; 30 days for retreatment. Note: Form must be completed in full. An incomplete form may be returned.

Serostim® Criteria:

- 1. The physician must first complete, sign, and date the Serostim PA form.
- 2. For initial therapy, or request for additional therapy, the physician must submit official medical records to support or answer all the questions addressed on the PA form, in addition to a six-month weight chronical indicating the most recent weights.
- 3. Recipient must 18 years of age or older.
- 4. Recipient must have a diagnosis of HIV associated wasting or cachexia.
- 5. Recipient must be on anti-retroviral therapy.
- 6. Recipient must have experienced at least a 7.5% unintentional weight loss within the last 6 months, 10% involuntary weight loss in last 12 months, or have a Body Mass Index (BMI) < 20 for initial approval.
- Alternatively, recipient may have a Body Cell Mass (BCM) < 35% (male) or <23% (female) of total body weight and a Body Mass Index less than 27. Another qualifier would be a greater than or equal to 5% BCM loss over 6 months. (ATTACH A SERIES OF BIOELECTRIC IMPEDANCE ANALYSIS [BIA] RESULTS IF APPLICABLE.)
- 8. Treatment must also include nutritional assessment and counseling. Total parenteral nutrition is sometimes of benefit in patients with damaged gastrointestinal tracts. Appetite stimulants such as megesterol may promote weight gain; however, most gain with megestrol acetate is in fat rather than BCM.
- 9. Serostim is contraindicated in patient's with active neoplasia.
- 10. Testosterone replacement therapy (minimum of 4 weeks) in hypogonadal men may increase lean body mass and muscle strength.
- 11. Oxandrolone has been found to produce significant increases in weight gain and BCM.
- 12. Dosage must be adjusted according to recipient's weight.

Weight Range	Dose							
>55kg (121 lb)	6 mg SC daily							
45-55kg (99-121 lb)	5 mg SC daily							
35-45kg (75-99 lb)	4 mg SC daily							
<35 kg(<75 lb)	0.1 mg/kg SC daily							

- 13. Length of therapy is 12 weeks; however, if a positive response to therapy (a 2% or greater increase in body weight and/or BCM) occurs but wasting is still evident, treatment may be continued and response reevaluated on a month-by-month basis. THEREFORE, RETREATMENT WILL BE APPROVED FOR A MAXIMUM OF 30 DAYS AT A TIME.
- 14. Physician must submit a new PA form for additional therapy.